Cardiomyocyte Cell Death Sits at the Center of Heart Disease Biology
Cardiomyocyte homeostasis is not a background detail in cardiovascular disease. It is the tissue-level balance that determines whether injured myocardium adapts, decompensates, or fails outright. In a heart with very limited regenerative capacity, each loss of viable muscle cell carries disproportionate weight, and programmed cell death becomes a central driver of disease progression rather than a downstream epiphenomenon.
This review places autophagy, apoptosis, and a broad family of regulated death programs at the center of cardiovascular pathobiology. The scope is wide: necroptosis, pyroptosis, ferroptosis, cuproptosis, disulfidptosis, necrosis induced by sodium overload, lysosomal cell death, oxeiptosis, PANoptosis, entotic cell death, netotic cell death, alkaliptosis, and PARP-1–dependent cell death. Each pathway represents a different molecular route to cardiomyocyte loss, yet the biology does not operate in isolation. Signaling networks overlap, amplify one another, and can shift a cell from stress adaptation to irreversible death.
A failing myocardium often dies by more than one mechanism at once.
Why Multiple Death Pathways Matter in a Single Cell Type
The attraction of this framework is practical. Cardiomyocytes are not passive victims of ischemia, inflammation, oxidative stress, or toxic injury; they respond through tightly regulated intracellular programs that determine survival or collapse. A single insult can trigger mitochondrial dysfunction, calcium overload, lipid peroxidation, inflammasome activation, and proteolytic failure in parallel. Once those signals intersect, the dominant death phenotype may no longer resemble classic apoptosis alone.
That complexity explains why this review emphasizes crosstalk among death programs rather than treating them as separate silos. Necroptosis and pyroptosis can intensify inflammatory injury. Ferroptosis ties cardiomyocyte death to iron handling and membrane lipid damage. PARP-1-dependent death reflects overwhelming DNA damage and energetic collapse. Even autophagy, which often supports survival by clearing damaged organelles and proteins, can become maladaptive when the process is excessive, stalled, or poorly timed.
The bedside consequence is straightforward: a heart that cannot regulate intracellular stress precisely enough loses contractile cells, then loses function.
Autophagy and Apoptosis as Adaptive and Maladaptive Forces
Among the pathways reviewed, autophagy and apoptosis remain the best characterized. Autophagy usually acts as a quality-control system, removing damaged mitochondria and misfolded proteins before they accumulate into lethal injury. In early or moderate stress, that mechanism can preserve cardiomyocyte function and reduce the burden of reactive oxygen species. When the stress becomes severe or persistent, however, the same machinery can become insufficient, dysregulated, or functionally exhausted.
Apoptosis sits in a more clearly destructive role, but even here the biological setting matters. In the myocardium, apoptotic loss of a relatively small number of cells can translate into measurable mechanical impairment when repeated over time or clustered in vulnerable regions. Mitochondrial pathways, death receptor signaling, and downstream caspase activation all contribute to this process. The review frames apoptosis not as an isolated endpoint but as part of a larger stress-response network shaped by inflammation, metabolic injury, and organelle failure.
Inflammation, Oxidative Stress, and Membrane Injury Drive Pathway Crosstalk
Several of the newer cell death programs are especially relevant because they connect cardiomyocyte injury to broader tissue inflammation. Pyroptosis directly links cell death to inflammatory mediator release, making it biologically suited to amplify myocardial damage after ischemia or persistent stress. Necroptosis similarly promotes membrane rupture and inflammatory spillover. In contrast, ferroptosis reflects a more metabolic form of injury, in which iron-dependent lipid peroxidation destabilizes the cell membrane and mitochondrial integrity.
This is where pathway crosstalk becomes clinically meaningful. Oxidative stress can push mitochondria toward apoptosis, promote lipid oxidation that favors ferroptosis, and intensify inflammatory signaling that supports pyroptosis or necroptosis. The same cardiomyocyte may traverse several of these states before it dies. For therapeutic development, that means single-target inhibition may be too narrow if the upstream injury is multifactorial.
Therapeutic Targets Will Need to Match the Dominant Injury State
The review argues for targeted intervention in cardiomyocyte programmed cell death as a route toward precision treatment in heart disease. That goal is plausible only if the dominant death program is identified correctly in a given clinical context. Ischemia-reperfusion injury, heart failure, hypertensive remodeling, metabolic stress, and inflammatory cardiomyopathy do not necessarily rely on the same death machinery. A therapy that attenuates apoptosis may not sufficiently blunt ferroptosis. An inhibitor of one inflammatory cascade may leave mitochondrial or lysosomal injury untouched.
Potential targets discussed across these pathways include molecules that control autophagy flux, caspase activation, inflammasome signaling, iron metabolism, redox balance, lysosomal stability, and PARP-1 activity. The translational challenge is to move from pathway catalogs to intervention points that can be drugged safely in a beating heart. Cardiomyocytes are uniquely sensitive to energetic disruption, so any inhibitor must reduce pathologic death without impairing essential stress adaptation.
Precision therapy in heart disease will depend on matching the inhibitor to the dominant death program.
What This Review Adds to Cardiovascular Research
The main value of this review is conceptual clarity. It consolidates a decade of work showing that cardiomyocyte death is not limited to a binary choice between survival and apoptosis. Instead, it emerges from an interconnected network of regulated death pathways that respond to metabolic stress, redox injury, calcium imbalance, DNA damage, and inflammation. That network model fits the way cardiovascular disease behaves at the tissue level: progressive, heterogeneous, and difficult to reverse once viable myocardium is lost.
For researchers, this framework supports biomarker discovery, mechanistic studies, and drug development centered on death-pathway signatures rather than single lesions in isolation. For clinicians, the implication is more immediate: myocardial injury is often determined long before overt pump failure becomes visible, and the intracellular response may shape the trajectory of disease as much as the initiating insult itself.
The review closes the distance between molecular pathology and therapeutic design, but several questions remain open. The field still needs stronger evidence linking specific cardiomyocyte death programs to defined cardiovascular phenotypes in human tissue, as well as safer inhibitors that can be translated into treatment without disrupting the normal stress responses the heart depends on every day.